Skip to main content
PCI Biotech Holding logo

PCI Biotech Holding — Investor Relations & Filings

Ticker · PCIB ISIN · NO0010405640 LEI · 5967007LIEEXZXFIGG77 OL Manufacturing
Open in API
Filings indexed 752 across all filing types
Latest filing 2026-02-09 Regulatory Filings
Country NO Norway
Listing OL PCIB

About PCI Biotech Holding

https://www.pcibiotech.no/

PCI Biotech Holding is a biopharmaceutical company developing therapeutic products based on its proprietary Photochemical Internalization (PCI) technology. This platform is a drug and nucleic acid delivery system designed to enhance the intracellular delivery of therapeutic molecules. The company's development programs are focused on applications in immunotherapy, dermatology, and bioprocessing for the manufacturing of viral vectors. A primary therapeutic area for the technology is cancer, where it aims to improve the efficacy of novel and existing treatments.

Recent filings

Filing Released Lang Actions
OSLO BØRS - STATUS COMPANIES PLACED IN RECOVERY BOX AND PENALTY BENCH
Regulatory Filings Classification · 95% confidence The document is a regulatory notice from Oslo Børs regarding the status of companies in the 'Recovery Box' and 'Penalty Bench'. It does not fit into specific categories like financial reports, M&A, or director dealings. As it is a general regulatory announcement regarding market status and compliance, it falls under the fallback category for regulatory filings.
2026-02-09 English
OSLO BØRS - STATUS COMPANIES PLACED IN RECOVERY BOX AND PENALTY BENCH
Regulatory Filings Classification · 95% confidence The document is a regulatory notice from Oslo Børs regarding the status of companies in the 'Recovery Box' and 'Penalty Bench'. It does not fit into specific categories like financial reports, M&A, or director dealings. As it is a general regulatory announcement regarding market status and compliance, it falls under the fallback category for regulatory filings.
2026-02-02 English
PCI Biotech Holding ASA is placed in Recovery Box
Regulatory Filings Classification · 95% confidence The document is a short announcement from Euronext Oslo Børs regarding the placement of PCI Biotech Holding ASA into the 'Recovery Box'. This is a regulatory notification concerning the status of the company's securities on the exchange. Since it does not fit into specific categories like delisting, share issues, or financial reports, it falls under the general regulatory announcement category.
2026-01-30 English
PCI Biotech initiates a process to evaluate the opportunity for a structured wind-up process
Regulatory Filings Classification · 95% confidence The document is a short, official stock exchange announcement regarding a material corporate event (the initiation of a structured wind-up process). It does not fit into specific categories like M&A (TAR) or financial reporting (10-K/IR), and it is not a report publication announcement (RPA) as it is the primary disclosure of the event itself. Given it is a regulatory disclosure of inside information under the EU Market Abuse Regulation, it falls under the general regulatory filing category.
2026-01-29 Norwegian
PCI Biotech announces discontinuation of R&D operations and continues evaluation of future options
Regulatory Filings Classification · 95% confidence The document is a short, official stock exchange announcement regarding the discontinuation of R&D operations and the evaluation of strategic alternatives (merger or wind-up). It is not a full report, but rather a regulatory disclosure of material information under the EU Market Abuse Regulation. Since it does not fit into specific categories like M&A (as it is a general strategic update) or financial reporting, it falls under the general regulatory filing category.
2026-01-08 English
PCI Biotech update
Regulatory Filings Classification · 95% confidence The document is a corporate update from PCI Biotech regarding its operational status, liquidity concerns, and management restructuring. It references previous announcements and interim reports but is not a report itself. It functions as a general regulatory disclosure under the Norwegian Securities Trading Act, providing material information about the company's going concern status and organizational changes. Since it does not fit into specific categories like M&A, dividends, or director dealings, it is classified as a general regulatory filing.
2025-10-23 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.